Characterization of the coexisting multiple mechanisms of methotrexate resistance in mouse 3T6 R50 fibroblasts.
We have studied the discrepancy in the degree of methotrexate (MTX) resistance that exists between two clonal cell lines, mouse 3T6 R50 cells and Chinese hamster ovary B11 0.5 cells that overexpress comparable levels of dihydrofolate reductase, yet exhibit a 100-fold difference in MTX resistance while maintaining similar sensitivity to the lipophilic antifolates trimetrexate and piritrexim. These data suggested that R50 cells may possess additional mechanism(s) of antifolate resistance, such as MTX transport alteration. Flow cytometric analysis using fluorescein methotrexate revealed comparable levels of fluorescein MTX displacement with lipophilic antifolates in viable R50 and B11 0.5 cells, but marked insensitivity of R50 cells to MTX competition, thus suggesting a poor uptake of MTX into R50 cells. Analysis of the kinetic parameters of dihydrofolate reductase from R50 cells neither showed alterations in enzyme affinities for various antifolates nor in the Michaelis constant for folic acid and NADPH nor a change in the pH activity optimum. R50 cell-free extracts contained wild-type levels of folylpoly-gamma-glutamyl synthetase activity. However, following metabolic labeling with [3H]MTX, no MTX polyglutamates could be detected in R50 cells. We conclude that the high level of MTX resistance in R50 cells is multifactorial, including overexpression of dihydrofolate reductase, reduced MTX transport, and possibly altered formation of MTX polyglutamates. The potential interactions between the different modalities of MTX resistance in R50 cells are being discussed.
Assaraf
Y G
YG
Department of Biology, Israel Institute of Technology, Haifa.
Feder
J N
JN
Sharma
R C
RC
Wright
J E
JE
Rosowsky
A
A
Shane
B
B
Schimke
R T
RT
D000818:Animals; D015152:Blotting, Northern; D015139:Blotting, Southern; D016466:CHO Cells; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002999:Clone Cells; D006224:Cricetinae; D004247:DNA / Q000235:genetics / Q000302:isolation & purification; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000502:physiology*; D015180:Electrophoresis, Gel, Two-Dimensional; D005347:Fibroblasts / Q000187:drug effects; D005434:Flow Cytometry; D005493:Folic Acid Antagonists / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D008727:Methotrexate / Q000494:pharmacology*; D051379:Mice; D014176:Protein Biosynthesis; D011506:Proteins / Q000302:isolation & purification; D011743:Pyrimidines / Q000494:pharmacology; D012313:RNA / Q000235:genetics / Q000302:isolation & purification; D013762:Tetrahydrofolate Dehydrogenase / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D013940:Thymidylate Synthase / Q000235:genetics; D016597:Trimetrexate / Q000494:pharmacology
D005493:Folic Acid Antagonists; D011506:Proteins; D011743:Pyrimidines; D012313:RNA; D004247:DNA; D013762:Tetrahydrofolate Dehydrogenase; D013940:Thymidylate Synthase; C024530:piritrexim; D016597:Trimetrexate; D008727:Methotrexate